BamSEC and AlphaSense Join Forces
Learn More
You must log in to view this page.

Inhibikase Therapeutics Inc. – Underwriting Agreements

NASDAQ: IKT    
Share price (4/6/26): $1.79    
Market cap (4/6/26): $236 million
Search in Documents
Key Exhibits
External Links

Underwriting Agreements Filter

EX-1
from SCHEDULE 13G/A 1 page Joint Acquisition Statement Pursuant to Section 240.13d-1
12/34/56
EX-1
from SCHEDULE 13G ~1 page Joint Filing Agreement
12/34/56
EX-1.1
from 8-K 47 pages 46,091,739 Shares and Pre-Funded Warrants to Purchase 22,873,779 Shares Inhibikase Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1
from SCHEDULE 13G/A 1 page Joint Acquisition Statement Pursuant to Section 240.13d-1
12/34/56
EX-1.2
from S-3 39 pages Open Market Sale Agreementsm
12/34/56
EX-1.1
from S-1/A 7 pages Placement Agency Agreement
12/34/56
EX-1.1
from S-1/A 7 pages Placement Agency Agreement
12/34/56
EX-1.1
from 8-K 50 pages Underwriting Agreement Between Inhibikase Therapeutics, Inc and Thinkequity, a Division of Fordham Financial Management, Inc. as Representative of the Several Underwriters Inhibikase Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.1
from S-1 50 pages Underwriting Agreement Between Inhibikase Therapeutics, Inc and Thinkequity, a Division of Fordham Financial Management, Inc. as Representative of the Several Underwriters Inhibikase Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.1
from DRS 50 pages Underwriting Agreement Between Inhibikase Therapeutics, Inc and Thinkequity, a Division of Fordham Financial Management, Inc. as Representative of the Several Underwriters Inhibikase Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.1
from S-1 52 pages Underwriting Agreement Between Inhibikase Therapeutics, Inc and Thinkequity, a Division of Fordham Financial Management, Inc. as Representative of the Several Underwriters Inhibikase Therapeutics, Inc. Underwriting Agreement
12/34/56